Adagene Inc ADR (ADAG)

$3.70 +0.04 (1.09%)
Market Cap 179.59M
Revenue (ttm) 7.67M
Net Income (ttm) -17.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -229.60%
Debt to Equity Ratio 0.05
Volume 29,300
Avg Vol 274,520
Day's Range N/A - N/A
Shares Out 47.39M
Stochastic %K 67%
Beta 0.57
Analysts Strong Sell
Price Target $9.40

Company Profile

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/met...

Industry: Biotechnology
Sector: Healthcare
Phone: 86 512 8777 3632
Address:
Building C14, 4th Floor No. 218, Xinghu Street Suzhou Industrial Park, Suzhou, China
BillionerOfKing
BillionerOfKing Apr. 29 at 6:53 PM
$ADAG Current Stock Price: $3.50
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 17 at 5:09 PM
$ADAG
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 14 at 9:42 PM
$ADAG RSI: 52.86, MACD: 0.1484 Vol: 0.26, MA20: 3.95, MA50: 3.45 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
DARKP00L
DARKP00L Apr. 6 at 11:59 AM
$ADAG 07:55 on Apr. 06 2026 Guggenheim Maintains Buy on Adagene, Raises Price Target to $10 #tradeideas
0 · Reply
BioTuesdays
BioTuesdays Apr. 2 at 12:49 PM
$ADAG and Incyte $INCY have announced a clinical collaboration to evaluate the combination of muzastotug (ADG126) and INCA33890, a TGFβR2 × PD-1 bispecific antibody, in patients with microsatellite stable colorectal cancer (MSS CRC) with or without liver metastases. https://biotuesdays.com/2026/04/02/adagene-and-incyte-collaborate-to-evaluate-combination-therapy-in-mss-crc-patients/
0 · Reply
DonCorleone77
DonCorleone77 Apr. 2 at 12:23 PM
$ADAG Adagene 18.666M share Spot Secondary priced at $3.75 Leerink and LifeSci Capital acted as joint book running managers for the offering.
0 · Reply
StocktwitsNews
StocktwitsNews Apr. 2 at 12:01 PM
Why Is ADAG Stock Tanking Pre-Market Today? $ADAG $PGJ https://stocktwits.com/news/equity/markets/why-is-adag-stock-tanking-today/cZ7xrbYRI8E
0 · Reply
focafoca99
focafoca99 Mar. 17 at 9:38 PM
$ADAG is getting two AACR presentations for ADG126, and the Morpheus Liver combo arm is probably the piece people will focus on first.
0 · Reply
StockScanners
StockScanners Mar. 12 at 3:34 AM
$ADAG keep watch if this holds above 3.22
0 · Reply
StockJelli
StockJelli Mar. 11 at 4:18 PM
Hope you all are making profits despite a slightly down market. Here are the top momentum stocks above an mcap of $100M $OCGN $ADAG $NVTS $HIMS $UAMY
0 · Reply
Latest News on ADAG
Adagene to Participate in Two Upcoming Investor Conferences

May 12, 2026, 8:30 AM EDT - 1 day ago

Adagene to Participate in Two Upcoming Investor Conferences

Adagene presents data from two Phase 1b/2 studies of muzastotug at AACR

2026-04-17T20:15:50.000Z - 26 days ago

Adagene presents data from two Phase 1b/2 studies of muzastotug at AACR

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types

Apr 17, 2026, 4:01 PM EDT - 26 days ago

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types

Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board

Apr 14, 2026, 7:00 AM EDT - 4 weeks ago

Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board

Adagene price target raised to $10 from $9 at Guggenheim

2026-04-06T10:45:27.000Z - 5 weeks ago

Adagene price target raised to $10 from $9 at Guggenheim

Adagene 18.666M share Spot Secondary priced at $3.75

2026-04-02T12:14:45.000Z - 5 weeks ago

Adagene 18.666M share Spot Secondary priced at $3.75

Adagene enters pact with Incyte for combination of muzastotug, INCA33890

2026-04-02T12:01:28.000Z - 5 weeks ago

Adagene enters pact with Incyte for combination of muzastotug, INCA33890

Adagene announces results from the latest data cut of muzastotug study

2026-04-02T11:55:00.000Z - 5 weeks ago

Adagene announces results from the latest data cut of muzastotug study

MRK

Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs

Apr 2, 2026, 7:10 AM EDT - 5 weeks ago

Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

Apr 2, 2026, 7:01 AM EDT - 5 weeks ago

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response

Apr 2, 2026, 7:00 AM EDT - 5 weeks ago

Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response

Adagene reports FY25 EPS (24c) vs (51c) last year

2026-04-01T21:06:08.000Z - 6 weeks ago

Adagene reports FY25 EPS (24c) vs (51c) last year

Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

Apr 1, 2026, 5:00 PM EDT - 6 weeks ago

Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA

Mar 17, 2026, 4:35 PM EDT - 2 months ago

Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA

Adagene Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 4:20 PM EDT - 2 months ago

Adagene Transcript: Leerink Global Healthcare Conference 2026

Adagene Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 4:00 PM EST - 2 months ago

Adagene Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Adagene provides objective for 2026

2026-01-23T13:11:24.000Z - 3 months ago

Adagene provides objective for 2026

Adagene Provides Business Update and 2026 Objectives

Jan 23, 2026, 8:00 AM EST - 3 months ago

Adagene Provides Business Update and 2026 Objectives

Adagene announces FDA fast track designation for muzastotug

2025-12-16T12:05:37.000Z - 5 months ago

Adagene announces FDA fast track designation for muzastotug

MRK

Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)

Dec 16, 2025, 7:00 AM EST - 5 months ago

Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)

Adagene initiated with a Buy at Guggenheim on muzastotug potential

2025-11-24T13:10:42.000Z - 6 months ago

Adagene initiated with a Buy at Guggenheim on muzastotug potential

Adagene initiated with a Buy at Guggenheim

2025-11-24T11:41:03.000Z - 6 months ago

Adagene initiated with a Buy at Guggenheim

Adagene initiated with an Outperform at LifeSci Capital

2025-11-14T11:26:15.000Z - 6 months ago

Adagene initiated with an Outperform at LifeSci Capital

Adagene announces licensing agreement with Third Arc Bio

2025-11-13T12:31:59.000Z - 6 months ago

Adagene announces licensing agreement with Third Arc Bio

Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Nov 13, 2025, 7:00 AM EST - 6 months ago

Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Adagene files to sell 10.625M ordinary shares or 8.5M ADSs for holders

2025-10-31T20:25:24.000Z - 6 months ago

Adagene files to sell 10.625M ordinary shares or 8.5M ADSs for holders

Adagene says first patient dosed in Phase 2 study of muzastotug, KEYTRUDA

2025-10-31T11:05:45.000Z - 6 months ago

Adagene says first patient dosed in Phase 2 study of muzastotug, KEYTRUDA

MRK

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

Oct 31, 2025, 7:00 AM EDT - 6 months ago

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

Adagene initiated with a Buy at Lucid Capital

2025-09-18T11:10:28.000Z - 8 months ago

Adagene initiated with a Buy at Lucid Capital

Adagene expands SAFEbody collaboration, license agreement with Exelixis

2025-09-16T12:05:19.000Z - 8 months ago

Adagene expands SAFEbody collaboration, license agreement with Exelixis

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

Sep 16, 2025, 8:00 AM EDT - 8 months ago

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

Adagene Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 7:00 AM EDT - 8 months ago

Adagene Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Adagene Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 11:00 AM EDT - 8 months ago

Adagene Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China

Sep 5, 2025, 9:55 AM EDT - 8 months ago

Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China

Adagene appoints Hoos as Executive Advisor

2025-09-03T13:15:51.000Z - 9 months ago

Adagene appoints Hoos as Executive Advisor

Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

Sep 3, 2025, 9:05 AM EDT - 9 months ago

Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

Adagene to Participate in Two Investor Conferences in September

Aug 26, 2025, 8:05 AM EDT - 9 months ago

Adagene to Participate in Two Investor Conferences in September

Adagene price target lowered to $7 from $8 at H.C. Wainwright

2025-08-15T10:20:45.000Z - 9 months ago

Adagene price target lowered to $7 from $8 at H.C. Wainwright

Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates

Aug 12, 2025, 4:05 PM EDT - 9 months ago

Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates

Adagene initiated with an Outperform at Leerink

2025-08-06T10:31:10.000Z - 10 months ago

Adagene initiated with an Outperform at Leerink

Adagene announces regulatory update on development plan for muzastotug

2025-07-15T11:05:12.000Z - 10 months ago

Adagene announces regulatory update on development plan for muzastotug

MRK

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

Jul 15, 2025, 7:00 AM EDT - 10 months ago

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

Jul 8, 2025, 7:00 AM EDT - 11 months ago

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

Adagene announces up to $25 million strategic investment from Sanofi

Jul 1, 2025, 7:00 AM EDT - 11 months ago

Adagene announces up to $25 million strategic investment from Sanofi

Adagene Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 9:20 AM EDT - 1 year ago

Adagene Transcript: Jefferies Global Healthcare Conference 2025

Adagene to Present at Jefferies Global Healthcare Conference 2025

May 27, 2025, 7:30 AM EDT - 1 year ago

Adagene to Present at Jefferies Global Healthcare Conference 2025

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025, 5:05 PM EDT - 1 year ago

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2025, 10:05 AM EDT - 1 year ago

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

Adagene Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 8, 2025, 12:30 PM EDT - 1 year ago

Adagene Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

Adagene Transcript: Leerink’s Global Healthcare Conference 2025

Mar 12, 2025, 10:40 AM EDT - 1 year ago

Adagene Transcript: Leerink’s Global Healthcare Conference 2025

Adagene to Present at Leerink's Global Healthcare Conference 2025

Mar 6, 2025, 8:00 AM EST - 1 year ago

Adagene to Present at Leerink's Global Healthcare Conference 2025

Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer

Feb 27, 2025, 8:00 AM EST - 1 year ago

Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer

CD47 Inhibitor Drug Clinical Trials Market Opportunity Outlook 2028, Competitive Analysis of Adagene, ALX, ImmuneOncia, ImmuneOnco, Light Chain Bioscience, Phanes, and Virtuoso,

Jan 29, 2025, 6:14 AM EST - 1 year ago

CD47 Inhibitor Drug Clinical Trials Market Opportunity Outlook 2028, Competitive Analysis of Adagene, ALX, ImmuneOncia, ImmuneOnco, Light Chain Bioscience, Phanes, and Virtuoso,

Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium

Jan 21, 2025, 5:00 PM EST - 1 year ago

Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Nov 7, 2024, 10:01 AM EST - 1 year ago

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 9, 2024, 6:00 AM EDT - 1 year ago

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Adagene Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 2:30 PM EDT - 1 year ago

Adagene Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Sep 16, 2024, 3:01 AM EDT - 1 year ago

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Adagene Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Adagene Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Adagene Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 6, 2024, 7:45 AM EDT - 1 year ago

Adagene Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September

Jul 12, 2024, 7:00 AM EDT - 1 year ago

Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September

Adagene to Present at Investor Conferences in June

May 22, 2024, 4:45 PM EDT - 2 years ago

Adagene to Present at Investor Conferences in June

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 29, 2024, 9:00 AM EDT - 2 years ago

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

Mar 7, 2024, 4:01 PM EST - 2 years ago

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

Feb 27, 2024, 8:00 AM EST - 2 years ago

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl

Feb 9, 2024, 6:00 AM EST - 2 years ago

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Jan 16, 2024, 5:01 PM EST - 2 years ago

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium

Jan 4, 2024, 5:00 AM EST - 2 years ago

Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium

Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023

Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Oct 12, 2023, 8:00 AM EDT - 2 years ago

Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Adagene to Present at Investor and Scientific Conferences in September

Sep 7, 2023, 6:00 AM EDT - 2 years ago

Adagene to Present at Investor and Scientific Conferences in September

Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update

Aug 31, 2023, 7:32 AM EDT - 2 years ago

Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update

Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate

May 4, 2023, 9:00 AM EDT - 3 years ago

Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate

Adagene Announces Updates to its Board of Directors

Apr 28, 2023, 7:00 AM EDT - 3 years ago

Adagene Announces Updates to its Board of Directors

Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors

Apr 18, 2023, 9:17 AM EDT - 3 years ago

Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors

Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 28, 2023, 4:30 PM EDT - 3 years ago

Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update

Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April

Mar 14, 2023, 6:00 PM EDT - 3 years ago

Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April

BillionerOfKing
BillionerOfKing Apr. 29 at 6:53 PM
$ADAG Current Stock Price: $3.50
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 17 at 5:09 PM
$ADAG
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 14 at 9:42 PM
$ADAG RSI: 52.86, MACD: 0.1484 Vol: 0.26, MA20: 3.95, MA50: 3.45 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
DARKP00L
DARKP00L Apr. 6 at 11:59 AM
$ADAG 07:55 on Apr. 06 2026 Guggenheim Maintains Buy on Adagene, Raises Price Target to $10 #tradeideas
0 · Reply
BioTuesdays
BioTuesdays Apr. 2 at 12:49 PM
$ADAG and Incyte $INCY have announced a clinical collaboration to evaluate the combination of muzastotug (ADG126) and INCA33890, a TGFβR2 × PD-1 bispecific antibody, in patients with microsatellite stable colorectal cancer (MSS CRC) with or without liver metastases. https://biotuesdays.com/2026/04/02/adagene-and-incyte-collaborate-to-evaluate-combination-therapy-in-mss-crc-patients/
0 · Reply
DonCorleone77
DonCorleone77 Apr. 2 at 12:23 PM
$ADAG Adagene 18.666M share Spot Secondary priced at $3.75 Leerink and LifeSci Capital acted as joint book running managers for the offering.
0 · Reply
StocktwitsNews
StocktwitsNews Apr. 2 at 12:01 PM
Why Is ADAG Stock Tanking Pre-Market Today? $ADAG $PGJ https://stocktwits.com/news/equity/markets/why-is-adag-stock-tanking-today/cZ7xrbYRI8E
0 · Reply
focafoca99
focafoca99 Mar. 17 at 9:38 PM
$ADAG is getting two AACR presentations for ADG126, and the Morpheus Liver combo arm is probably the piece people will focus on first.
0 · Reply
StockScanners
StockScanners Mar. 12 at 3:34 AM
$ADAG keep watch if this holds above 3.22
0 · Reply
StockJelli
StockJelli Mar. 11 at 4:18 PM
Hope you all are making profits despite a slightly down market. Here are the top momentum stocks above an mcap of $100M $OCGN $ADAG $NVTS $HIMS $UAMY
0 · Reply
jacksparo
jacksparo Mar. 11 at 4:14 PM
$ADAG From my special list Nov Copy 2025! Today got to my projected exit at 4.50 From below 1.50 average entry! All documented ✅✅!
0 · Reply
topstockalerts
topstockalerts Mar. 11 at 3:56 PM
$ADAG Following this closely as it continues to build momentum. Buyers are in control. Could be more upside ahead.
0 · Reply
aquira
aquira Mar. 11 at 3:00 PM
$ADAG yessssiirrrr
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 28 at 4:15 AM
$ADAG RSI: 58.64, MACD: 0.2245 Vol: 0.24, MA20: 3.01, MA50: 2.37 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
VolatilityClustering
VolatilityClustering Feb. 20 at 1:51 PM
$ADAG Adagene develops antibody-based cancer therapies. Clinical milestones drive valuation. Development risk remains elevated.
0 · Reply
jacksparo
jacksparo Feb. 18 at 4:42 PM
$ADAG In the right path from my Special list. My suggested entry last were among the best for this one so far up big here!
0 · Reply
jacksparo
jacksparo Feb. 17 at 6:58 PM
$CABA $ADAG They can’t beat me in those bios!!! Every thing as planned ✅✅! I am still sharing my live updates only in the Live Telegram biotech group 📈📈📈!
0 · Reply